Compare · KIDS vs WST
KIDS vs WST
Side-by-side comparison of OrthoPediatrics Corp. (KIDS) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KIDS and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $23.71B, about 41.9x KIDS ($566.1M).
- Over the past year, KIDS is up 11.6% and WST is up 34.9% - WST leads by 23.2 points.
- KIDS has been more active in the news (8 items in the past 4 weeks vs 4 for WST).
- WST has more recent analyst coverage (19 ratings vs 8 for KIDS).
- Company
- OrthoPediatrics Corp.
- West Pharmaceutical Services Inc.
- Price
- $21.54-0.62%
- $344.43+2.02%
- Market cap
- $566.1M
- $23.71B
- 1M return
- -11.23%
- -2.08%
- 1Y return
- +11.64%
- +34.87%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 8
- 4
- Recent ratings
- 8
- 19
OrthoPediatrics Corp.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest KIDS
- Director Pelizzon David R sold $6,352,773 worth of shares (302,369 units at $21.01) (SEC Form 4)
- Large owner Squadron Capital Llc sold $7,761,194 worth of shares (336,831 units at $23.04) (SEC Form 4)
- Large owner Pritzker Jennifer N. sold $7,761,194 worth of shares (336,831 units at $23.04) (SEC Form 4)
- Director Pelizzon David R sold $7,761,194 worth of shares (336,831 units at $23.04) (SEC Form 4)
- Large owner Pritzker Jennifer N. sold $943,302 worth of shares (38,300 units at $24.63) (SEC Form 4)
- Large owner Squadron Capital Llc sold $943,302 worth of shares (38,300 units at $24.63) (SEC Form 4)
- Director Pelizzon David R sold $943,302 worth of shares (38,300 units at $24.63) (SEC Form 4)
- OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations
- SEC Form 10-Q filed by OrthoPediatrics Corp.
- OrthoPediatrics Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest WST
- SEC Form 4 filed by President and CEO Lagarde Michel
- New insider Lagarde Michel claimed ownership of 7,850 shares (SEC Form 3)
- UBS resumed coverage on West Pharm with a new price target
- West to Participate in Upcoming Investor Conferences
- SVP & Chief Financial Officer Mcmahon Robert W. converted options into 7,149 shares and covered exercise/tax liability with 3,109 shares, increasing direct ownership by 136% to 7,021 units (SEC Form 4)
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target